Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · as published 2026-01-23 View official record Methodology

Covered recipient · General Payments record

JUAN E LERMA

Allopathic & Osteopathic Physicians Internal Medicine Nephrology

NPI
1841279981
CMS profile
219856
Location
EVERGREEN PARK, IL

General Payments · PY2018–2024

$237,031.21

  • Reported across 153 records
  • CMS publication 2026-01-23

Latest program year · PY2024

$45,886.26

33 records · 0 disputed

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How these totals are calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

PY2024 · sorted by reported total

By paying entity

PY2024 · sorted by reported total

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2018 $90.05 1
PY2019 $9,855.00 8
PY2020 $13,897.81 12
PY2021 $23,070.94 17
PY2022 $72,228.19 41
PY2023 $72,002.96 41
PY2024 $45,886.26 33

Payment records · PY2024 (33)

Sorted by paying entity, then date · as published by CMS

Program year 2024 201820192020202120222023 Record-level detail is published for PY2024; earlier years are summarised in “By program year”.
Paying entity Amount Date Nature of payment Dispute status Published Record ID Source
Amgen Inc. $120.00 10/23/2024 Food and Beverage Undisputed 01/23/2026 1117610017 CMS
Amgen Inc. $130.57 10/23/2024 Food and Beverage Undisputed 01/23/2026 1117610019 CMS
Amgen Inc. $1,314.00 11/05/2024 Consulting Fee Undisputed 01/23/2026 1117309297 CMS
Ardelyx, Inc. $16.50 09/19/2024 Food and Beverage Undisputed 01/23/2026 1146692042 CMS
Bayer Healthcare Pharmaceuticals Inc. $60.57 11/16/2024 Travel and Lodging Undisputed 01/23/2026 1086079092 CMS
Bayer Healthcare Pharmaceuticals Inc. $4,410.00 11/16/2024 Consulting Fee Undisputed 01/23/2026 1086202516 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $30.26 07/17/2024 Food and Beverage Undisputed 01/23/2026 1118176895 CMS
CALLIDITAS THERAPEUTICS US INC. $750.00 01/18/2024 Honoraria Undisputed 01/23/2026 1141508361 CMS
CALLIDITAS THERAPEUTICS US INC. $1,000.00 06/05/2024 Honoraria Undisputed 01/23/2026 1141516443 CMS
CALLIDITAS THERAPEUTICS US INC. $142.85 10/01/2024 Food and Beverage Undisputed 01/23/2026 1141523789 CMS
CALLIDITAS THERAPEUTICS US INC. $2,000.00 10/21/2024 Consulting Fee Undisputed 01/23/2026 1141525106 CMS
GlaxoSmithKline, LLC. $650.00 04/12/2024 Consulting Fee Undisputed 01/23/2026 1116323366 CMS
Mallinckrodt Hospital Products Inc. $141.16 07/17/2024 Food and Beverage Undisputed 01/23/2026 1145098681 CMS
Novartis Pharmaceuticals Corporation $2,600.00 06/21/2024 Consulting Fee Undisputed 01/23/2026 1087109978 CMS
Novartis Pharmaceuticals Corporation $30.05 11/13/2024 Food and Beverage Undisputed 01/23/2026 1087109982 CMS
Novo Nordisk Inc $1,125.00 11/04/2024 Consulting Fee Undisputed 01/23/2026 1097339317 CMS
OPKO Pharmaceuticals, LLC $5,058.00 12/24/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Undisputed 01/23/2026 1112846632 CMS
Otsuka Pharmaceutical Development & Commercialization, Inc. $3,400.00 04/22/2024 Consulting Fee Undisputed 01/23/2026 1118837913 CMS
Otsuka Pharmaceutical Development & Commercialization, Inc. $2,720.00 05/30/2024 Consulting Fee Undisputed 01/23/2026 1118837915 CMS
Otsuka Pharmaceutical Development & Commercialization, Inc. $3,650.00 11/05/2024 Consulting Fee Undisputed 01/23/2026 1118837917 CMS
SCPHARMACEUTICALS INC. $1,750.00 04/26/2024 Consulting Fee Undisputed 01/23/2026 1132271129 CMS
SCPHARMACEUTICALS INC. $1,000.00 10/09/2024 Consulting Fee Undisputed 01/23/2026 1132302819 CMS
Travere Therapeutics, Inc. $2,500.00 04/02/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Undisputed 01/23/2026 1149920701 CMS
Travere Therapeutics, Inc. $1,500.00 04/09/2024 Consulting Fee Undisputed 01/23/2026 1149900464 CMS
Travere Therapeutics, Inc. $2,000.00 04/16/2024 Consulting Fee Undisputed 01/23/2026 1149900468 CMS
Travere Therapeutics, Inc. $4,800.00 05/07/2024 Consulting Fee Undisputed 01/23/2026 1149920705 CMS
Travere Therapeutics, Inc. $127.59 08/09/2024 Food and Beverage Undisputed 01/23/2026 1149943645 CMS
Travere Therapeutics, Inc. $238.26 09/20/2024 Travel and Lodging Undisputed 01/23/2026 1149943649 CMS
Travere Therapeutics, Inc. $405.16 09/20/2024 Food and Beverage Undisputed 01/23/2026 1149943653 CMS
Travere Therapeutics, Inc. $30.11 10/14/2024 Travel and Lodging Undisputed 01/23/2026 1149943637 CMS
Travere Therapeutics, Inc. $19.42 10/16/2024 Food and Beverage Undisputed 01/23/2026 1149943633 CMS
Travere Therapeutics, Inc. $66.76 10/24/2024 Food and Beverage Undisputed 01/23/2026 1149943641 CMS
VERTEX PHARMACEUTICALS INCORPORATED $2,100.00 12/18/2024 Consulting Fee Undisputed 01/23/2026 1105906569 CMS

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-01-23
Program years on this page
2018, 2019, 2020, 2021, 2022, 2023, 2024
Source files
Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.